Nanoparticle-Mediated Drug Delivery in Inflammatory Bowel Disease

Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, arises from a complex interplay of genetic susceptibility, immune dysregulation and microbiota imbalance. Conventional treatments often suffer from limited efficacy, systemic toxicity and poor localisation to inflamed sites. Nanoparticle-mediated drug delivery offers a versatile platform to address these challenges by encapsulating therapeutic agents within sub-micrometre carriers that enhance stability in the gastrointestinal milieu, prolong retention at the disease locus and release payloads in a controlled or stimuli-responsive manner. Strategies include mucoadhesive coatings to increase residence time, pH-sensitive matrices to bypass the upper gut, and redox- or enzyme-responsive linkages that trigger drug discharge within inflamed tissues. Beyond small-molecule drugs, emerging nanocarriers can transport peptides, nucleic acids and biologics, while simultaneously modulating the gut microbiome and epithelial barrier. Together, these advances aim to maximise local efficacy, reduce off-target effects and open new avenues for precision therapy in IBD management.

Research from Nature Portfolio

Recent studies have demonstrated a bioadhesive liquid coacervate formed by hydrogen-bonded nanoparticle assembly, which adheres uniformly to the intestinal mucosa and sustains small-molecule drug release over several days, significantly alleviating acute colitis in animal models and restoring microbial diversity. Foundational work on zinc oxide nanoparticles revealed their intrinsic antioxidant and anti-inflammatory properties, activating the Nrf2 pathway, suppressing pro-inflammatory cytokines and synergising with mesalazine to enhance therapeutic outcomes, thereby underscoring the potential of inorganic nanoparticles as adjuncts in IBD therapy.

Nanoparticle-Mediated Drug Delivery in Inflammatory Bowel Disease publication trend

The graph below shows the total number of articles in nanoparticle-mediated drug delivery in inflammatory bowel disease across all publications each year (not limited to Nature Index journals).

Technical terms

Nanoparticle: A colloidal carrier of 1–1000 nm used to encapsulate and protect therapeutic agents for targeted delivery.

Mucoadhesion: The capacity of a material to adhere to mucus layers, prolonging residence time at mucosal surfaces.

Reactive oxygen species (ROS): Chemically reactive molecules derived from oxygen that increase at inflammation sites and can trigger stimuli-responsive release.

Bioadhesive coacervate: A fluid phase formed by nanoparticle assembly that strongly adheres to biological surfaces, enabling sustained drug release.

Exosome-like nanovesicles: Naturally derived, cell-secreted vesicles or plant-derived analogues used to deliver bioactive cargo with inherent targeting properties.

References

1. Colon‐Targeted Adhesive Hydrogel Microsphere for Regulation of Gut Immunity and Flora. Advanced Science (2021).
2. A Proresolving Peptide Nanotherapy for Site‐Specific Treatment of Inflammatory Bowel Disease by Regulating Proinflammatory Microenvironment and Gut Microbiota. Advanced Science (2019).
3. Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy. Nature Communications (2021).
4. Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy. Journal of Nanobiotechnology (2022).
5. ZnO nanoparticles act as supportive therapy in DSS-induced ulcerative colitis in mice by maintaining gut homeostasis and activating Nrf2 signaling. Scientific Reports (2017).